Ads
related to: treatment for lytic bone lesions multiple myeloma- Contact a Representative
For Questions and Information
About This Treatment
- Primary and Subgroup Data
Primary- and Subgroup-
Specific Data
- Patient Profile
Potential Treatment Candidates
HCPs, See Who May Be Appropriate
- Phase 3 Trial
Explore the Phase 3 Trial Design,
Results, and Patient Population
- Contact a Representative
alternativebee.com has been visited by 10K+ users in the past month
benchmarkguide.com has been visited by 10K+ users in the past month
Search results
Results from the WOW.Com Content Network
Osteolytic lesion at the bottom of the radius, diagnosed by a darker section that indicates a loss of bone density. An osteolytic lesion (from the Greek words for "bone" (ὀστέον), and "to unbind" (λύειν)) is a softened section of a patient's bone formed as a symptom of specific diseases, including breast cancer and multiple myeloma.
Multiple myeloma is diagnosed based on blood or urine tests finding abnormal antibody proteins (often using electrophoretic techniques revealing the presence of a monoclonal spike in the results, termed an m-spike), bone marrow biopsy finding cancerous plasma cells, and medical imaging finding bone lesions. [6]
The proposed criteria for SPB is the presence of a single bone lesion, normal bone marrow (less than 5% plasma cells), small or no paraprotein, no related organ involvement/damage and a normal skeletal survey (other than the single bone lesion). The criteria for extramedullary plasmacytoma are the same but the tumor is located in soft tissue.
Bence Jones proteins are particularly diagnostic of multiple myeloma in the context of target organ manifestations such as kidney failure, lytic (or "punched out") bone lesions, anemia, or large numbers of plasma cells in the bone marrow. Bence Jones proteins are present in 2/3 of multiple myeloma cases. [3]
Treatment of patients with this POEMS syndrome variant who have evidence of bone lesions and/or myeloma proteins are the same as those for POEMS syndrome patients. In the absence of these features, treatment with rituximab , a monoclonal antibody preparation directed against B cells bearing the CD20 antigen, or siltuximab , a monoclonal ...
Multiple myeloma is a hematologic cancer, originating in the bone marrow, which also frequently presents as one or more bone lesions. [ 10 ] Germ cell tumors , including teratoma , often present and originate in the midline of the sacrum, coccyx, or both.
Ads
related to: treatment for lytic bone lesions multiple myelomaalternativebee.com has been visited by 10K+ users in the past month
benchmarkguide.com has been visited by 10K+ users in the past month